NorthSea Therapeutics

NorthSea Therapeutics: Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. NST licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS, who developed LovazaÒ (US brand, branded OmacorÒ in Europe), a blockbuster cardiovascular drug. Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. Two additional SEFAs are in clinical development; SEFA 1024 is in phase 1 to be developed for dyslipidemia and SEFA 6179, to be developed for the orphan indication IFALD, will enter phase 1 in Q421.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Other
Clinical Stage
Phase l or ll
Disease Space
Fibrosis, Metabolic Disorders
Finance
Pre-Revenues
Industry
Biotechnology
Investment Participation
CrossOvers, IPO
Listing
Private
Market Cap
Private
Therapeutic Modalities
Small Molecule
Website:
Profiles:
Address:
Gooimeer 2 35
Naarden, Noord-Holland 1411 DC
The Netherlands

Company Participants at NorthSea Therapeutics NASH Virtual KOL Call with Dr. John Kastelein

  • Rob de Ree, Chief Executive Officer & Board Member

Upcoming Company Event Participation